Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma

Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma

AbstractIn this study, a novel series of histone deacetylases 6 (HDAC6) inhibitors containing polycyclic aromatic rings were discovered and evaluated for their pharmacological activities. The most potent compound 10c exhibited high HDAC6 inhibitory activity (IC50 = 261 nM) and excellent HDAC6 select...

Full description

Bibliographic Details
Main Authors: Xiaopeng Peng, Ziwen Yu, Goverdhan Surineni, Bulian Deng, Meizhu Zhang, Chuan Li, Zhiqiang Sun, Wanyi Pan, Yao Liu, Shenglan Liu, Bin Yu, Jianjun Chen
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
HDAC6
inhibitor
tubastatin A
anticancer activity
antitumor immunity
Online Access:https://www.tandfonline.com/doi/10.1080/14756366.2023.2201408

Internet

https://www.tandfonline.com/doi/10.1080/14756366.2023.2201408

Similar Items